Cargando…

Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols

Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanaan, Ahmad Seif, Jakubovski, Ewgeni, Müller-Vahl, Kirsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447929/
https://www.ncbi.nlm.nih.gov/pubmed/28445405
http://dx.doi.org/10.3390/brainsci7050047
_version_ 1783239457766375424
author Kanaan, Ahmad Seif
Jakubovski, Ewgeni
Müller-Vahl, Kirsten
author_facet Kanaan, Ahmad Seif
Jakubovski, Ewgeni
Müller-Vahl, Kirsten
author_sort Kanaan, Ahmad Seif
collection PubMed
description Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff/day (= 100 μL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 × 3 puffs/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting.
format Online
Article
Text
id pubmed-5447929
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54479292017-05-30 Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols Kanaan, Ahmad Seif Jakubovski, Ewgeni Müller-Vahl, Kirsten Brain Sci Case Report Early anecdotal reports and preliminary studies suggested that cannabinoid-based medicines such as delta-9-tetrahydrocannabinol (THC) are effective in the treatment of Gilles de la Tourette syndrome (TS). We report a single case study of a patient with otherwise treatment-resistant TS successfully treated with nabiximols. Our patient was a 22-year-old male suffering from severe and complex TS. Treatment with nabiximols was commenced at a dose of 1 puff/day (= 100 μL containing 2.7 mg THC and 2.5 mg cannabidiol (CBD)) and slowly increased up to a dosage of 3 × 3 puffs/day (= 24.3 mg THC and 22.5 mg CBD). Several clinical measures for tics, premonitory urges, and global impairment were acquired before and after two weeks of treatment. Treatment with nabiximols resulted in major improvements of both tics and premonitory urges, but also global impairment and health-related quality of life according to all used measurements without causing relevant adverse effects. Our results provide further evidence that treatment with nabiximols may be effective in the treatment of patients with TS. Given the positive response exhibited by the patient highlighted in this report, further investigation of the effects of nabiximols is proposed on a larger group of patients in a clinical trial setting. MDPI 2017-04-26 /pmc/articles/PMC5447929/ /pubmed/28445405 http://dx.doi.org/10.3390/brainsci7050047 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Kanaan, Ahmad Seif
Jakubovski, Ewgeni
Müller-Vahl, Kirsten
Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
title Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
title_full Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
title_fullStr Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
title_full_unstemmed Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
title_short Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols
title_sort significant tic reduction in an otherwise treatment-resistant patient with gilles de la tourette syndrome following treatment with nabiximols
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447929/
https://www.ncbi.nlm.nih.gov/pubmed/28445405
http://dx.doi.org/10.3390/brainsci7050047
work_keys_str_mv AT kanaanahmadseif significantticreductioninanotherwisetreatmentresistantpatientwithgillesdelatourettesyndromefollowingtreatmentwithnabiximols
AT jakubovskiewgeni significantticreductioninanotherwisetreatmentresistantpatientwithgillesdelatourettesyndromefollowingtreatmentwithnabiximols
AT mullervahlkirsten significantticreductioninanotherwisetreatmentresistantpatientwithgillesdelatourettesyndromefollowingtreatmentwithnabiximols